{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T13:54:23Z","timestamp":1791640463612,"version":"4.3.4"},"reference-count":68,"publisher":"Elsevier BV","issue":"9","content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Autoimmunity Reviews"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1016\/j.autrev.2013.03.004","type":"journal-article","created":{"date-parts":[[2013,3,25]],"date-time":"2013-03-25T15:07:31Z","timestamp":1364224051000},"page":"931-935","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":87,"title":["Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase"],"prefix":"10.1016","volume":"12","author":[{"given":"Amelia","family":"Evoli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Padua","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.autrev.2013.03.004_bb0005","doi-asserted-by":"crossref","first-page":"401","DOI":"10.3109\/08916930903563491","article-title":"Thymic remodeling associated with hyperplasia in myasthenia gravis","volume":"43","author":"Le Panse","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.004_bb0010","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1097\/WCO.0b013e328357a829","article-title":"Autoimmune mechanisms in myasthenia gravis","volume":"25","author":"Cavalcante","year":"2012","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0015","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1196\/annals.1405.018","article-title":"Common cellular and diverse genetic basis of thymoma-associated myasthenia gravis. Role of MHC Class II and AIRE genes and genetic polymorphisms","volume":"1132","author":"Str\u00f6bel","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.004_bb0020","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.autrev.2013.03.007","article-title":"The different roles of the thymus in the pathogenesis of the various myasthenia gravis subtypes","volume":"12","author":"Marx","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0355","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1212\/01.WNL.0000150587.71497.B6","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"64","author":"Lauriola","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0025","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1002\/ana.20386","article-title":"Fewer thymic changes in MuSK antibody-positive than in MuSK antibody-negative MG","volume":"57","author":"Leite","year":"2005","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0030","doi-asserted-by":"crossref","first-page":"353","DOI":"10.3109\/08916930903555943","article-title":"Antibody effector mechanisms in myasthenia gravis-Pathogenesis at the neuromuscular junction","volume":"43","author":"Gomez","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.004_bb0035","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1016\/j.autrev.2013.03.001","article-title":"Pathophysiology of myasthenia gravis with antibodies to acetylcholine receptor, muscle-specific kinase and low-density lipoprotein-related receptor protein 4","volume":"12","author":"Verschuuren","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0040","doi-asserted-by":"crossref","first-page":"798","DOI":"10.1016\/j.ajpath.2011.10.031","article-title":"Antibodies against muscle-specific kinase impair both presynaptic and postsynaptic functions in a murine model of myasthenia gravis","volume":"180","author":"Mori","year":"2012","journal-title":"Am J Pathol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0050","doi-asserted-by":"crossref","first-page":"A383","DOI":"10.1016\/j.autrev.2009.11.011","article-title":"Geoepidemiology of myasthenia gravis","volume":"9","author":"Meyer","year":"2010","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0055","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1111\/j.1468-1331.2005.01137.x","article-title":"Seronegative myasthenia gravis: disease severity and prognosis","volume":"12","author":"Romi","year":"2005","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0060","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1196\/annals.1405.012","article-title":"Response to therapy in myasthenia gravis with anti-MuSK antibodies","volume":"1132","author":"Evoli","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.004_bb0065","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1212\/01.wnl.0000254620.45529.97","article-title":"Clinical comparison of anti-MuSK- vs antiAChR-positive and seronegative myasthenia gravis","volume":"68","author":"Deymeer","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0075","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1196\/annals.1405.020","article-title":"Myasthenia gravis seronegative for acetylcholine receptor antibody","volume":"1132","author":"Vincent","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.004_bb0080","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/mus.21191","article-title":"Racial differences in myasthenia gravis in Alabama","volume":"39","author":"Oh","year":"2009","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0085","doi-asserted-by":"crossref","first-page":"53","DOI":"10.3988\/jcn.2009.5.2.53","article-title":"Muscle specific receptor tyrosine kinase antibody positive myasthenia gravis current status","volume":"5","author":"Oh","year":"2009","journal-title":"J Clin Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0090","doi-asserted-by":"crossref","first-page":"1772","DOI":"10.1212\/01.wnl.0000218159.79769.5c","article-title":"Strong association of MuSK antibody-positive myasthenia gravis and HLA-DR14 DQ5","volume":"66","author":"Niks","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0095","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1212\/01.wnl.0000339103.08830.86","article-title":"HLA class II allele analysis in MuSK-positive myasthenia gravis suggests a role for DQ5","volume":"72","author":"Bartoccioni","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0100","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1016\/j.autrev.2011.10.022","article-title":"Genes, epigenetic regulation and environmental factors: Which is the most relevant in developing autoimmune diseases?","volume":"11","author":"Costenbader","year":"2012","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0105","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1007\/s00415-005-0032-8","article-title":"MuSK-antibody positive pure ocular myasthenia gravis","volume":"253","author":"Hanisch","year":"2006","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0110","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1002\/mus.22006","article-title":"Anti-MuSK antibody myasthenia gravis: clinical finding and response to therapy in two large cohorts","volume":"44","author":"Guptill","year":"2011","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0115","doi-asserted-by":"crossref","first-page":"2304","DOI":"10.1093\/brain\/awg223","article-title":"Clinical correlates with anti-MuSK antibodies in generalized seronegative myasthenia gravis","volume":"126","author":"Evoli","year":"2003","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.004_bb0120","doi-asserted-by":"crossref","first-page":"1481","DOI":"10.1093\/brain\/awl095","article-title":"MRI and clinical studies of facial and bulbar involvement in MuSK antibody-associated myasthenia gravis","volume":"129","author":"Farrugia","year":"2006","journal-title":"Brain"},{"key":"10.1016\/j.autrev.2013.03.004_bb0125","doi-asserted-by":"crossref","first-page":"2065","DOI":"10.1016\/j.clinph.2005.06.003","article-title":"MuSK-antibody positive myasthenia gravis: clinical and electrodiagnostic patterns","volume":"116","author":"Stickler","year":"2005","journal-title":"Clin Neurophysiol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0130","doi-asserted-by":"crossref","first-page":"671","DOI":"10.2169\/internalmedicine.44.671","article-title":"Myasthenia gravis with anti-MuSK antibody, showing progressive muscular atrophy without blepharoptosis","volume":"44","author":"Ishii","year":"2005","journal-title":"Intern Med"},{"key":"10.1016\/j.autrev.2013.03.004_bb0135","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1552-6569.2009.00456.x","article-title":"MRI evidence of early muscle atrophy in MuSK positive myasthenia gravis","volume":"21","author":"Zouvelou","year":"2011","journal-title":"J Neuroimaging"},{"key":"10.1016\/j.autrev.2013.03.004_bb0140","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.jneuroim.2008.05.032","article-title":"MuSK-antibody positive myasthenia gravis. Questions from the clinic","volume":"201\u2013202","author":"Sanders","year":"2008","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0145","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.expneurol.2011.04.018","article-title":"Muscle-selective synaptic disassembly and reorganization in MuSK antibody positive MG mice","volume":"230","author":"Punga","year":"2011","journal-title":"Exp Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0150","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.jneuroim.2005.08.016","article-title":"MuSK antibody positive myasthenia gravis plasma modifies MURF-1 expression in C2C12 cultures and mouse muscle in vivo","volume":"170","author":"Bienveniste","year":"2005","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0155","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.autrev.2013.03.002","article-title":"Serological diagnostics in myasthenia gravis based on novel assays and recently identified antigens","volume":"12","author":"Zisimopoulou","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0160","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1055\/s-2008-1041255","article-title":"Diagnosis of myasthenia gravis in the 1990s","volume":"10","author":"Phillips","year":"1990","journal-title":"Semin Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0165","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1212\/01.wnl.0000183145.91579.74","article-title":"Nonresponsiveness to anticholinesterase agents in patients with anti-MuSK-antibody-positive MG","volume":"65","author":"Hatanaka","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0170","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1212\/WNL.0b013e318237f660","article-title":"Anti-MuSK autoantibodies block binding of collagen Q to MuSK","volume":"77","author":"Kawakami","year":"2011","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0175","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1016\/j.autrev.2013.03.005","article-title":"Mechanisms associated with the pathogenicity of antibodies against muscle-specific kinase in myasthenia gravis","volume":"12","author":"Mori","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0180","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1002\/(SICI)1097-4598(199609)19:9<1069::AID-MUS1>3.0.CO;2-Y","article-title":"AAEM minimonograph #25: single-fiber electromyography","volume":"19","author":"Sanders","year":"1996","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0185","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1002\/mus.20498","article-title":"Repetitive nerve stimulation of facial muscles in MuSK antibody positive myasthenia gravis","volume":"33","author":"Oh","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0190","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1212\/01.wnl.0000228225.23349.5d","article-title":"Anti-MuSK antibodies: correlation with myasthenia gravis severity","volume":"67","author":"Bartoccioni","year":"2006","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0195","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1038\/ncpneuro0526","article-title":"Antibodies to AChR, MuSK and VGKC in a patient with myasthenia gravis and Morvan's syndrome","volume":"3","author":"D\u00edaz-Manera","year":"2007","journal-title":"Nat Clin Pract Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0200","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1002\/ana.22312","article-title":"Autoantibodies to low-density lipoprotein receptor-related protein 4 in myasthenia gravis","volume":"69","author":"Higuchi","year":"2011","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0205","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1001\/archneurol.2011.2393","article-title":"Autoantibodies to lipoprotein-related protein 4 in patients with double-seronegative myasthenia gravis","volume":"69","author":"Zhang","year":"2012","journal-title":"Arch Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0210","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1002\/mus.20030","article-title":"Clinical evaluation and management of myasthenia gravis","volume":"29","author":"Keesey","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0215","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1196\/annals.1405.036","article-title":"Treatment and clinical research in myasthenia gravis. How far have we come?","volume":"1132","author":"Barohn","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.004_bb0220","doi-asserted-by":"crossref","first-page":"1652","DOI":"10.1212\/01.WNL.0000098887.24618.A0","article-title":"Treatment of autoimmune myasthenia gravis","volume":"61","author":"Richman","year":"2003","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0225","doi-asserted-by":"crossref","first-page":"428","DOI":"10.3109\/08916930903518107","article-title":"Immunosuppressive treatment of myasthenia gravis","volume":"43","author":"Sanders","year":"2010","journal-title":"Autoimmunity"},{"key":"10.1016\/j.autrev.2013.03.004_bb0360","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.autrev.2007.01.001","article-title":"Therapeutic options in autoimmune myasthenia gravis","volume":"6","author":"Garc\u00eda-Carrasco","year":"2007","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0365","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1016\/j.autrev.2008.04.011","article-title":"Role of natural antibodies in immune homeostasis: IVIg perspective","volume":"7","author":"Vani","year":"2008","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0235","doi-asserted-by":"crossref","first-page":"1099","DOI":"10.1136\/jnnp.2004.052415","article-title":"The features of myasthenia gravis with autoantibodies to MuSK","volume":"76","author":"Lavrnic","year":"2005","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.004_bb0240","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1002\/mus.20515","article-title":"Cholinergic neuromuscular hyperactivity in patients with myasthenia gravis seropositive for MuSK antibody","volume":"34","author":"Punga","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0245","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1002\/mus.20069","article-title":"Clinical comparison of muscle-specific tyrosine kinase (MuSK) antibody-positive and -negative myasthenic patients","volume":"30","author":"Zhou","year":"2004","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0250","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1111\/j.1468-1331.2007.01870.x","article-title":"Clinical and experimental features of MuSK antibody positive MG in Japan","volume":"14","author":"Ohta","year":"2007","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0255","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/j.1468-1331.2008.02176.x","article-title":"MuSK-positive myasthenia gravis is rare in the Polish population","volume":"15","author":"Kostera-Pruszczyk","year":"2008","journal-title":"Eur J Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0260","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1212\/01.wnl.0000267694.45244.f4","article-title":"Anti-MuSK antibody after thymectomy in a previously seropositive myasthenic child","volume":"69","author":"Saulat","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0265","doi-asserted-by":"crossref","first-page":"1780","DOI":"10.1007\/s00415-009-5215-2","article-title":"Juvenile seropositive myasthenia gravis with anti-MuSK antibody after thymectomy","volume":"256","author":"Kostera-Pruszczyk","year":"2009","journal-title":"J Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0275","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1212\/WNL.65.5.782","article-title":"Thymus changes in anti-MuSK-positive and -negative myasthenia gravis","volume":"65","author":"Saka","year":"2005","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0280","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1097\/CND.0b013e318137a24b","article-title":"Clinical review of muscle-specific tyrosine kinase-antibody positive myasthenia gravis","volume":"8","author":"Wolfe","year":"2007","journal-title":"J Clin Neuromuscul Dis"},{"key":"10.1016\/j.autrev.2013.03.004_bb0290","first-page":"A299","article-title":"Muscle antibody positive myasthenia gravis: response to treatment in 31 patients","volume":"68","author":"Sanders","year":"2007","journal-title":"Neurology"},{"key":"10.1016\/j.autrev.2013.03.004_bb0295","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1097\/WCO.0b013e32833c0982","article-title":"Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis","volume":"23","author":"Guptill","year":"2010","journal-title":"Curr Opin Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0300","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1002\/mus.21533","article-title":"Clinical findings in MuSK-antibody positive myasthenia gravis: a U.S. experience","volume":"41","author":"Pasnoor","year":"2010","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0305","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1136\/jnnp.2009.171793","article-title":"Is tongue atrophy reversible in anti-MuSK myasthenia gravis? Six-year observation","volume":"81","author":"Takahashi","year":"2010","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.004_bb0310","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1196\/annals.1405.033","article-title":"Rebooting the immune system with high-dose cyclophosphamide for treatment of refractory myasthenia gravis","volume":"1132","author":"Drachman","year":"2008","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.autrev.2013.03.004_bb0315","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1002\/ana.10400","article-title":"Treatment of refractory myasthenia: \u201crebooting\u201d with high-dose cyclophosphamide","volume":"5","author":"Drachman","year":"2003","journal-title":"Ann Neurol"},{"key":"10.1016\/j.autrev.2013.03.004_bb0320","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1002\/mus.20411","article-title":"High-dose cyclophosphamide in refractory myasthenia gravis with anti-MuSK antibodies","volume":"33","author":"Lin","year":"2006","journal-title":"Muscle Nerve"},{"key":"10.1016\/j.autrev.2013.03.004_bb0325","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1124\/pr.109.002006","article-title":"Therapeutic targeting of B cells for rheumatic autoimmune diseases","volume":"63","author":"Engel","year":"2011","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0330","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.autrev.2009.08.007","article-title":"Current status on B-cell depletion therapy in autoimmune diseases other than rheumatoid arthritis","volume":"9","author":"D\u00f6rner","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0335","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.autrev.2013.03.011","article-title":"Ectopic germinal centers, BAFF and anti-B cell therapy in Myasthenia Gravis","volume":"12","author":"Berrih-Aknin","year":"2013","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.autrev.2013.03.004_bb0340","first-page":"90","article-title":"Sustained response to rituximab in anti-AChR and anti-MuSK positive myasthenia gravis","volume":"201\u2013202","author":"Illa","year":"2008","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.004_bb0345","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1136\/jnnp.2009.197632","article-title":"The use of rituximab in myasthenia gravis and Lambert\u2013Eaton myasthenic syndrome","volume":"82","author":"Maddison","year":"2011","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"10.1016\/j.autrev.2013.03.004_bb0350","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1212\/WNL.0b013e3182407982","article-title":"Long-lasting treatment effect of rituximab in MuSK myasthenia","volume":"78","author":"D\u00ecaz-Manera","year":"2012","journal-title":"Neurology"}],"container-title":["Autoimmunity Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721300030X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S156899721300030X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,10,17]],"date-time":"2018-10-17T19:23:14Z","timestamp":1539804194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S156899721300030X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,7]]},"references-count":68,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["S156899721300030X"],"URL":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.004","relation":{},"ISSN":["1568-9972"],"issn-type":[{"value":"1568-9972","type":"print"}],"subject":[],"published":{"date-parts":[[2013,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and therapy of myasthenia gravis with antibodies to muscle-specific kinase","name":"articletitle","label":"Article Title"},{"value":"Autoimmunity Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.autrev.2013.03.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}